Y-mAbs Therapeutics Inc. (YMAB) Fundamentals

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.
SHARE INFORMATION
Market Cap$ 480,025,452
Shares Outstanding43,718,165
Float36,414,802
Percent Float83.29%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 34,897,000
Latest Fiscal EPS$ -1.29
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions303
Institutional Holdings Date2022-04-30
Institutional Bought Previous 3 Months4,027,264
Institutional Holdings Percent117.8%
Institutional Sold Previous 3 Months5,020,668
Insider Holdings Date2022-03-31
Insider Bought Previous 3 Months16,000
Insider Holdings Percent1.0
Insider Sold Previous 3 Months806,288
Insider Shares Owned422,480
TRADING INFO
52 Week High$ 39.82
52 Week Low$ 6.50
52 Week High Change$ -70.15
21 Day Moving Average$ 9.5933
21 Day Extended Moving Average$ 10.1687
50 Day Moving Average$ 11.125
50 Day Extended Moving Average$ 10.5387
200 Day Moving Average$ 17.4735
200 Day Extended Moving Average$ 16.8034
10 Day Average Volume374,554
20 Day Average Volume580,731
30 Day Average Volume519,153
50 Day Average Volume470,442
Alpha-0.027548
Beta1.4690
Standard Deviation0.159797
R20.249930
7 Day Price Change$ 1.10
7 Day Percent Change11.13%
21 Day Price Change$ 1.64
21 Day Percent Change17.56%
30 Day Price Change$ 1.47
30 Day Percent Change15.46%
Month to Date Price Change$ 2.58
Month to Date Percent Change30.71%
Quarter to Date Price Change$ -0.90
Quarter to Date Percent Change-7.58%
180 Day Price Change$ -6.17
180 Day Percent Change-35.98%
200 Day Price Change$ -11.25
200 Day Percent Change-50.61%
Year to Date Price Change$ -5.23
Year to Date Percent Change-32.26%

Y-mAbs Therapeutics Inc. (YMAB) Key Ratios

PROFITABILITY
EBIT Margin-287.2%
EBITDA Margin-285.1%
Pre-Tax Profit Margin0.0%
Profit Margin Count-72.66%
Gross Margin89.4%
Profit Margin TOT-72.66%
INCOME STATEMENTS
Revenue$ 40,000,000
Revenue Per Share$ 0.915
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book3.00
Total Debt To Equity0.00
Int Coverage-60.90
Current Ratio6.10
Leverage Ratio1.20
Quick Ratio5.70
Long Term Debt To Capital0.01
VALUATION MEASURES
PE Ratio-4.00
Enterprise Value$ 314,546,547
Price to Sales12.0006
Price to Free Cash-4.90
PE High Last 5 Years0.00
Price To Book3.00
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book3.00
MANAGEMENT EFFECTIVENESS
Receivables Turnover5.20
Invoice Turnover1.30
Assets Turnover0.10
Return Assets-50.11
Return on Equity-57.00
Return on Capital-55.20

Y-mAbs Therapeutics Inc. (YMAB) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorPricewaterhouseCoopers LLP
CEOThomas Gad
Emplyoees148
Last AuditUQ
CIK0001722964
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address230 Park Avenue
Suite 3350
New York, NY 10169
Websitehttps://www.ymabs.com
Facsimile-
Telephone+1 646 885-8505
Emailinfo@ymabs.com


Your Recent History
NASDAQ
YMAB
Y mAbs The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.